Novo Nordisk plans new study for CagriSema, targets 2026 submission
CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...
Ozempic Could Get Way Too Expensive Under Trump—Here's What You Can Do
While it may seem strange that politics could impact the price of popular weight loss drugs, it is a definite possibility.
The Obesity Market Is Growing Just Fine. But Investors Want to Know What’s Next
Eli Lilly and Novo Nordisk have both assuaged investor concerns over near-term growth. Now the focus shifts back to their ...
RTE Online12h
Eli Lilly forecasts 2025 profit growth after recent weight-loss drug worries
Eli Lilly has today forecast annual profit largely above Wall Street estimates, providing some relief to investors after ...
Wegovy maker Novo Nordisk says surging growth driving emissions higher
Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as ...
Zawya15h
Stocks rise, Treasury yields under pressure
SINGAPORE/NEW YORK - Global shares rose on Thursday in a modest relief rally as fears of an escalating trade war between the U.S. and its major trading partners ebbed, while U.S. Treasury yields came ...
New Atlas16h
Ozempic is suspected in more cases of sudden vision loss
Scientists remain puzzled as to why some individuals taking popular weight loss and diabetes medications such as Ozempic and ...
GSK tells Labour to back British firms after Astra bust-up
Chief executive Emma Walmsley said ministers must work with the sector to boost investment amid growing concerns about doing ...
Novo Nordisk Outlook Provides Some Welcome Relief
The company's shares rose as investors breathed a sigh of relief on strong sales growth and guidance, despite ongoing ...